ActiveMax® Human IL-6 (IL6-H4218) is expressed from human 293 cells (HEK293). It contains AA Val 30 - Met 212 (Accession # NP_000591).
Predicted N-terminus: Val 30
This protein carries no "tag".
The protein has a calculated MW of 20.8 kDa. The protein migrates as 24-27 kDa under reducing (R) condition (SDS-PAGE) due to different glycosylation.
Less than 1.0 EU per μg by the LAL method.
>98% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
No activity loss is observed after storage at:
- 4-8°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ActiveMax® Human IL-6 on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 98%.
Immobilized Human IL-6, Tag Free (Catalog # IL6-H4218) at 5 μg/mL (100 μL/well) can bind Biotinylated Human IL-6 R alpha, His Tag (Catalog # CD6-H82E8) with a linear range of 4-125 ng/mL.
Interleukin 6 (IL-6) is also known as HGF, BSF2,HSF, IFNB2 and IL-6, originally identified as a B cell differentiation factor, is a multifunctional cytokine that regulates immune responses, hematopoiesis, acute phase responses, and inflammatory reactions.It is secreted by T cells, macrophages , monocytes, fibroblasts,endothelial cells,et.al. to stimulate immune response to trauma, especially burns or other tissue damage leading to inflammation. Interleukin 6 has been shown to interact with interleukin-6 receptor and glycoprotein. IL-6 is relevant to many disease processes such as diabetes,atherosclerosis, depression,Alzheimer's Disease,systemic,lupus erythematosus,prostate cancer and rheumatoid arthritis. Advanced/metastatic cancer patients have higher levels of IL-6 in their blood.Hence there is an interest in developing anti-IL-6 agents as therapy against many of these diseases.
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.